Aridis Pharmaceuticals, Inc.
5941 Optical Court
San Jose
California
95138
United States
Tel: 408-385-1742
Fax: 408-960-3822
Website: http://www.aridispharma.com/
91 articles with Aridis Pharmaceuticals, Inc.
-
Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update
5/16/2022
Aridis Pharmaceuticals, Inc. reported financial and corporate results for its first quarter ended March 31, 2022.
-
Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update
3/31/2022
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, reported financial and corporate results for its fourth quarter and year ended December 31, 2021.
-
Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals
2/17/2022
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced that both of its fully human monoclonal antibodies in the AR-701 cocktail neutralized the SARS-CoV-2 Omicron variant.
-
Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission
1/27/2022
Funding from the Bill & Melinda Gates Foundation will support the development of Aridis' inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19.
-
In the last two years, the sheer volume of scientific research focused on COVID-19 has been astounding—thousands of clinical studies, dozens of vaccines and new compounds, and hundreds of approved drugs tested for efficacy against COVID-19.
-
A Perfect Storm of Superbugs
1/17/2022
To alleviate the problem of antibiotic-resistant bacteria, or superbugs, several biotechnology companies are developing different strategies to target and kill these microorganisms. -
Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses
12/21/2021
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced that its fully human monoclonal antibody cocktail AR-701 is broadly reactive against the Omicron and other COVID-19 variants, SARS, MERS, and seasonal human coronaviruses.
-
Aridis Pharmaceuticals Announces Third Quarter 2021 Results
11/10/2021
Aridis Pharmaceuticals, Inc. today reported financial and corporate results for its third quarter ended September 30, 2021.
-
Aridis Pharmaceuticals Announces Second Quarter 2021 Results
8/12/2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2021.
-
Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market
8/2/2021
Aridis Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,947,556 shares of the Company's common stock
-
Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)
7/26/2021
Aridis Pharmaceuticals announced today that animal efficacy data reported by the Coronavirus Immunotherapeutics Consortium (CoVIC) showed that the Company's COVID-19 monoclonal antibody (mAb) AR-711, one of two mAbs in the AR-712 cocktail, ranks among the top 5 most potent mAbs that the CoVIC consortium have studied to date.
-
Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca
7/19/2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to in-license the late stage monoclonal antibody candidate, suvratoxumab.
-
Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant
7/12/2021
Texas Biomedical Research Institute and Aridis' data confirmed AR-712 binds to and neutralizes the Delta variant of SARS-CoV-2 virus
-
Aridis Pharmaceuticals Announces First Quarter 2021 Results
5/11/2021
Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, reported financial and corporate results for the first quarter ended March 31, 2021.
-
Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update
3/30/2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the fourth quarter ended December 31, 2020.
-
Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
3/26/2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced an interview with Vu Truong, Ph.D., Chief Executive Officer will air on The RedChip Money Report®
-
Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode
3/8/2021
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. Kermode works on vaccines and mAbs for zoonotic viruses, which are animal viruses that have the ability to infect humans.
-
Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants
2/23/2021
National Institute of Allergy and Infectious Disease (NIAID) and the Coronavirus Immunotherapy Consortium (CoVIC) are providing preclinical services support to accelerate development
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
-
Aridis' COVID-19 therapy is particularly exciting. AR-711 is an inhaled, self-administered, at-home treatment for mild-to-moderate SARS-CoV-2 infections.